Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9460847 | 0.79 | POLB (0.40) | TDP1KDM4ENPC1HTTCYP11B1 | |
| SCHEMBL8413080 | 0.78 | TDP1 (0.48) | TDP1HTTCYP11B1CYP11B2TNF | |
| SCHEMBL6530090 | 0.76 | TDP1 (0.46) | TDP1KDM4ENPC1HTTCYP11B1 | |
| SCHEMBL9060998 | 0.75 | TDP1 (0.48) | TDP1HTTCYP11B1CYP11B2TNF | |
| SCHEMBL1939000 | 0.74 | TDP1 (0.44) | TDP1HTTCYP11B1CYP11B2TNF | |
| SCHEMBL10735469 | 0.73 | TDP1 (0.43) | TDP1KDM4ENPC1HTTCYP11B1 | |
| SCHEMBL11269104 | 0.73 | KDM4E (0.44) | KDM4ENPC1HTTEGLN3ASAH1 | |
| SCHEMBL8792548 | 0.72 | TDP1 (0.46) | TDP1HTTCYP11B1CYP11B2TNF | |
| SCHEMBL11451311 | 0.72 | TDP1 (0.46) | TDP1KDM4EHTTCYP11B1CYP11B2 | |
| SCHEMBL6529410 | 0.72 | CYP11B1 (0.53) | TDP1NPC1HTTCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795445-B2 | Substituted 2-aminoalkylthiobenzimidazole compounds, pharmaceutical compositions thereof and methods for their use | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-7795445-B2 | Substituted 2-aminoalkylthiobenzimidazole compounds, pharmaceutical compositions thereof and methods for their use | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-7795445-B2 | Substituted 2-aminoalkylthiobenzimidazole compounds, pharmaceutical compositions thereof and methods for their use | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| EP-1874737-B1 | SUBSTITUTED 2-AMINOALKYLTHIO-BENZIMIDAZOLES AND USE THEREOF FOR REDUCING BLOOD SUGAR LEVELS | SANOFI AVENTIS (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20080090889-A1 | SUBSTITUTED 2-AMINOALKYLTHIOBENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080090889-A1 | SUBSTITUTED 2-AMINOALKYLTHIOBENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| EP-1874737-A1 | SUBSTITUTED 2-AMIN0ALKYLTHI0-BENZIMIDAZ0LES AND USE THEREOF FOR REDUCING BLOOD SUGAR LEVELS | sanofi-aventis (FR) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874737-A1 | SUBSTITUTED 2-AMIN0ALKYLTHI0-BENZIMIDAZ0LES AND USE THEREOF FOR REDUCING BLOOD SUGAR LEVELS | sanofi-aventis (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111261-A1 | SUBSTITUTED 2-AMIN0ALKYLTHI0-BENZIMIDAZ0LES AND USE THEREOF FOR REDUCING BLOOD SUGAR LEVELS | SANOFI-AVENTIS (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111261-A1 | SUBSTITUTED 2-AMIN0ALKYLTHI0-BENZIMIDAZ0LES AND USE THEREOF FOR REDUCING BLOOD SUGAR LEVELS | SANOFI-AVENTIS (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090889-A1 | SUBSTITUTED 2-AMINOALKYLTHIOBENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | SLC5A2, GPR119, SLC2A2 | TDP1 1920/4885KDM4E 1610/4885NPC1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.